Gene Therapies: The Challenge of Manufacturing Personalized Treatments at Scale

Exclusive interview with Eduardo Bravim discussing the manufacturing, regulatory, and scalability challenges of personalized gene and cell therapies. Originally published by Guairá News.

Gene and cell therapies represent one of the most promising frontiers in modern medicine — offering targeted, and in many cases personalized, treatment options for patients with rare genetic disorders, oncologic conditions and previously untreatable diseases.

But scaling these therapies from clinical breakthrough to broadly accessible treatment is a complex industrial and regulatory challenge. Unlike traditional pharmaceuticals, advanced therapies often require patient-specific manufacturing, tightly controlled cold chains, specialized bioreactors, and highly qualified personnel — creating pressure on cost, timelines, and global access.

The report published by Guairá News examines how the pharmaceutical industry is confronting these challenges, including investments in dedicated biomanufacturing sites, automation of cell processing, digitalization of production records, and closer coordination with regulatory agencies to ensure safety, traceability, and reproducibility at scale.

This is a summary of an external publication. For the full content, please refer to the original article at Guairá News.